Dassault Systèmes is reported to be in talks to acquire ArisGlobal, a software company used for drug trial management, in a deal valued at about $2 billion. The Financial Times reports that ArisGlobal would be bought from a Swedish buyout group. If completed, the acquisition would expand Dassault Systèmes’ presence in life sciences software, aligning with the company’s broader strategy to grow in that sector.
The reports describe the discussions as ongoing and do not provide confirmation of final terms, deal timing, or whether regulatory approvals would be required. No additional details on how Dassault Systèmes would pay for the transaction, the extent of ArisGlobal’s product portfolio, or the rationale beyond strategic fit are included in the information provided by the sources.
Overall, both outlets indicate that the prospective acquisition is in the negotiation stage and centered on Dassault Systèmes’ efforts to strengthen its life sciences offering through the purchase of drug trial software capabilities.
